Developing models for cachexia and their implications in drug discovery

Bibliography

• Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr 2008;27(6):793-9
   PubMed Web of Science ®Google Scholar
• Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncology 2011;12(5):489-95
   PubMed Web of Science ®Google Scholar
• Muscaritoli M, Anker SD, Argiles J, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic wasting diseases” and “nutrition in geriatrics”. Clin Nutr 2010;29(2):154-9
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1(1):1-5
   PubMed Web of Science ®Google Scholar
• von Haehling S, Anker SD. Prevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014. J Cachexia Sarcopenia Muscle 2014;5(4):261-3
   PubMed Web of Science ®Google Scholar
• Fearon KC. Cancer cachexia and fat-muscle physiology. N Engl J Med 2011;365(6):565-7
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C. Inflammation and ovarian cancer. Cytokine 2012;58(2):133-47
   PubMed Web of Science ®Google Scholar
• Maccio A, Madeddu C. The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review. J Mol Med (Berlin, Germany) 2013;91(12):1355-68
   PubMed Web of Science ®Google Scholar
• Bennani-Baiti N, Walsh D. Animal models of the cancer anorexia-cachexia syndrome. Supportive care in cancer 2011;19(9):1451-63
   PubMed Web of Science ®Google Scholar
• Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Dis 2014;14(1):58-74
   Web of Science ®Google Scholar
• Argiles JM, Busquets S, Stemmler B, Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer 2014;14(11):754-62
   PubMed Web of Science ®Google Scholar
• Vaughan VC, Martin P, Lewandowski PA. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachexia Sarcopenia Muscle 2013;4(2):95-109
   Google Scholar
• Tan BH, Fearon KC. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11(4):400-7
   PubMed Web of Science ®Google Scholar
• Deboer MD. Animal models of anorexia and cachexia. Expert Opin Drug Discov 2009;4(11):1145-55
   PubMed Web of Science ®Google Scholar
• Llovera M, Carbo N, Lopez-Soriano J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 1998;133(1):83-7
   PubMed Web of Science ®Google Scholar
• Ham DJ, Murphy KT, Chee A, et al. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia. Clin Nutr 2014;33(3):448-58
   PubMed Web of Science ®Google Scholar
• Tschirner A, von Haehling S, Palus S, et al. Ursodeoxycholic acid treatment in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle 2012;3(1):31-6
   Google Scholar
• Baltgalvis KA, Berger FG, Pena MM, et al. Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice. J Appl Physiol (1985) 2010;109(4):1155-61
   PubMed Web of Science ®Google Scholar
• Puppa MJ, White JP, Sato S, et al. Gut barrier dysfunction in the Apc(Min/+) mouse model of colon cancer cachexia. Biochim Biophys Acta 2011;1812(12):1601-6
   PubMed Web of Science ®Google Scholar
• Baltgalvis KA, Berger FG, Pena MM, et al. Interleukin-6 and cachexia in ApcMin/+ mice. Am J Physiol Regul Integr Comp Physiol 2008;294(2):R393-401
   PubMed Web of Science ®Google Scholar
• Baltgalvis KA, Berger FG, Pena MM, et al. Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc (Min/+) mouse. Pflugers Arch 2009;457(5):989-1001
   PubMed Web of Science ®Google Scholar
• White JP, Puppa MJ, Gao S, et al. Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK. Am J Physiol Endocrinol Metab 2013;304(10):E1042-52
   PubMed Web of Science ®Google Scholar
• White JP, Puppa MJ, Narsale A, Carson JA. Characterization of the male ApcMin/+ mouse as a hypogonadism model related to cancer cachexia. Biology open 2013;2(12):1346-53
   PubMed Web of Science ®Google Scholar
• Velazquez KT, Enos RT, Narsale AA, et al. Quercetin supplementation attenuates the progression of cancer cachexia in ApcMin/+ mice. J Nutrition 2014;144(6):868-75
   PubMed Web of Science ®Google Scholar
• Adams JM, Harris AW, Pinkert CA, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985;318(6046):533-8
   PubMed Web of Science ®Google Scholar
• Robert F, Mills JR, Agenor A, et al. Targeting protein synthesis in a Myc/mTOR-driven model of anorexia-cachexia syndrome delays its onset and prolongs survival. Cancer Res 2012;72(3):747-56
   PubMed Web of Science ®Google Scholar
• Yanagihara K, Takigahira M, Mihara K, et al. Inhibitory effects of isoflavones on tumor growth and cachexia in newly established cachectic mouse models carrying human stomach cancers. Nutr Cancer 2013;65(4):578-89
   PubMed Web of Science ®Google Scholar
• Terawaki K, Sawada Y, Kashiwase Y, et al. New cancer cachexia rat model generated by implantation of a peritoneal dissemination-derived human stomach cancer cell line. Am J Physiol Endocrinol Metab 2014;306(4):E373-87
   PubMed Web of Science ®Google Scholar
• Fujitsuka N, Asakawa A, Uezono Y, et al. Potentiation of ghrelin signaling attenuates cancer anorexia-cachexia and prolongs survival. Translational psychiatry 2011;1:e23
   Google Scholar
• Takeda H, Sadakane C, Hattori T, et al. Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism. Gastroenterology 2008;134(7):2004-13
   PubMed Web of Science ®Google Scholar
• Suominen MI, Rissanen JP, Kakonen R, et al. Survival benefit with radium-223 dichloride in a mouse model of breast cancer bone metastasis. J Natl Cancer Inst 2013;105(12):908-16
   PubMed Web of Science ®Google Scholar
• Sun X, Jiang R, Przepiorski A, et al. “Iron-saturated” bovine lactoferrin improves the chemotherapeutic effects of tamoxifen in the treatment of basal-like breast cancer in mice. BMC Cancer 2012;12:591
   PubMed Web of Science ®Google Scholar
• Jiang M, Xu X, Bi Y, et al. Systemic inflammation promotes lung metastasis via E-selectin upregulation in mouse breast cancer model. Cancer biology & therapy 2014;15(6):789-96
   PubMed Web of Science ®Google Scholar
• Gordon AH, O’Keefe RJ, Schwarz EM, et al. Nuclear factor-kappaB-dependent mechanisms in breast cancer cells regulate tumor burden and osteolysis in bone. Cancer Res 2005;65(8):3209-17
   PubMed Web of Science ®Google Scholar
• Dupuy E, Hainaud P, Villemain A, et al. Tumoral angiogenesis and tissue factor expression during hepatocellular carcinoma progression in a transgenic mouse model. J Hepatol 2003;38(6):793-802
   PubMed Web of Science ®Google Scholar
• Dubois N, Bennoun M, Allemand I, et al. Time-course development of differentiated hepatocarcinoma and lung metastasis in transgenic mice. J Hepatol 1991;13(2):227-39
   PubMed Web of Science ®Google Scholar
• Abstracts of the 7th cachexia conference, Kobe/Osaka, Japan, December 9-11, 2013 (part 2). J Cachexia Sarcopenia Muscle 2014;5(1):35-78
   PubMed Web of Science ®Google Scholar
• Palazon A, Goldrath AW, Nizet V, Johnson RS. HIF transcription factors, inflammation, and immunity. Immunity 2014;41(4):518-28
   PubMed Web of Science ®Google Scholar
• Schenk E, Hendrickson AE, Northfelt D, et al. Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies. Invest New Drugs 2013;31(5):1251-6
   PubMed Web of Science ®Google Scholar
• Bowles DW, Ma WW, Senzer N, et al. A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer 2013;109(5):1085-92
   PubMed Web of Science ®Google Scholar
• Lee K, Kim HM, A novel approach to cancer therapy using PX-478 as a HIF-1alpha inhibitor. Arch Pharm Res 2011;34(10):1583-5
   PubMed Web of Science ®Google Scholar
• Hill JA, Olson EN. Cardiac plasticity. N Engl J Med 2008;358(13):1370-80
   PubMed Web of Science ®Google Scholar
• Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2010;142(4):531-43
   PubMed Web of Science ®Google Scholar
• Costelli P, De Tullio R, Baccino FM, Melloni E. Activation of Ca(2+)-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer 2001;84(7):946-50
   PubMed Web of Science ®Google Scholar
• Springer J, Tschirner A, Haghikia A, et al. Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. Eur Heart J 2014;35(14):932-41
   PubMed Web of Science ®Google Scholar
• Springer J, Tschirner A, Hartman K, et al. The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy. Int J Cardiol 2013;168(4):3527-31
   PubMed Web of Science ®Google Scholar
• Springer J, Tschirner A, Hartman K, et al. Inhibition of xanthine oxidase reduces wasting and improves outcome in a rat model of cancer cachexia. Int J Cancer 2012;131(9):2187-96
   PubMed Web of Science ®Google Scholar
• Elkina Y, Palus S, Tschirner A, et al. Tandospirone reduces wasting and improves cardiac function in experimental cancer cachexia. Int J Cardiol 2013;170(2):160-6
   PubMed Web of Science ®Google Scholar
• Xu H, Crawford D, Hutchinson KR, et al. Myocardial dysfunction in an animal model of cancer cachexia. Life Sci 2011;88(9-10):406-10
   PubMed Web of Science ®Google Scholar
• Tian M, Asp ML, Nishijima Y, Belury MA. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice. Int J Oncol 2011;39(5):1321-6
   PubMed Web of Science ®Google Scholar
• Cosper PF, Leinwand LA. Cancer causes cardiac atrophy and autophagy in a sexually dimorphic manner. Cancer Res 2011;71(5):1710-20
   PubMed Web of Science ®Google Scholar
• Farkas J, von Haehling S, Kalantar-Zadeh K, et al. Cachexia as a major public health problem: frequent, costly, and deadly. J Cachexia Sarcopenia Muscle 2013;4(3):173-8
   Google Scholar
• von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther 2009;121(3):227-52
   PubMed Web of Science ®Google Scholar
• Li P, Waters RE, Redfern SI, et al. Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice. Am J Pathol 2007;170(2):599-608
   PubMed Web of Science ®Google Scholar
• Geng T, Li P, Yin X, Yan Z. PGC-1alpha promotes nitric oxide antioxidant defenses and inhibits FOXO signaling against cardiac cachexia in mice. Am J Pathol 2011;178(4):1738-48
   PubMed Web of Science ®Google Scholar
• Okutsu M, Call JA, Lira VA, et al. Extracellular superoxide dismutase ameliorates skeletal muscle abnormalities, cachexia, and exercise intolerance in mice with congestive heart failure. Circ Heart Fail 2014;7(3):519-30
   PubMed Web of Science ®Google Scholar
• Kato T, Niizuma S, Inuzuka Y, et al. Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circ Heart Fail 2010;3(3):420-30
   PubMed Web of Science ®Google Scholar
• Kato T, Niizuma S, Inuzuka Y, et al. Analysis of liver metabolism in a rat model of heart failure. Int J Cardiol 2012;161(3):130-6
   PubMed Web of Science ®Google Scholar
• Fricker M, Deane A, Hansbro PM. Animal models of chronic obstructive pulmonary disease. Expert Opin Drug Discov 2014;9(6):629-45
   PubMed Web of Science ®Google Scholar
• Furuya K, Kawahara N, Kawai K, et al. Proximal occlusion of the middle cerebral artery in C57Black6 mice: relationship of patency of the posterior communicating artery, infarct evolution, and animal survival. J Neurosurg 2004;100(1):97-105
   PubMed Web of Science ®Google Scholar
• Jonsson AC, Lindgren I, Norrving B, Lindgren A. Weight loss after stroke: a population-based study from the Lund Stroke Register. Stroke 2008;39(3):918-23
   PubMed Web of Science ®Google Scholar
• Hafer-Macko CE, Yu S, Ryan AS, et al. Elevated tumor necrosis factor-alpha in skeletal muscle after stroke. Stroke 2005;36(9):2021-3
   PubMed Web of Science ®Google Scholar
• Meisel C, Schwab JM, Prass K, et al. Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci 2005;6(10):775-86
   PubMed Web of Science ®Google Scholar
• Springer J, Schust S, Peske K, et al. Catabolic signaling and muscle wasting after acute ischemic stroke in mice: indication for a stroke-specific sarcopenia. Stroke 2014;45(12):3675-83
   PubMed Web of Science ®Google Scholar
• McKinnell IW, Rudnicki MA. Molecular mechanisms of muscle atrophy. Cell 2004;119(7):907-10
   PubMed Web of Science ®Google Scholar
• Acharyya S, Butchbach ME, Sahenk Z, et al. Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 2005;8(5):421-32
   PubMed Web of Science ®Google Scholar
• Zhu Y, Fotinos A, Mao LL, et al. Neuroprotective agents target molecular mechanisms of disease in ALS. Drug Discov Today 2015;20(1):65-75
   PubMed Web of Science ®Google Scholar
• Kiaei M, Petri S, Kipiani K, et al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2006;26(9):2467-73
   PubMed Web of Science ®Google Scholar
• Neymotin A, Petri S, Calingasan NY, et al. Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220(1):191-7
   PubMed Web of Science ®Google Scholar
• Wu AS, Kiaei M, Aguirre N, et al. Iron porphyrin treatment extends survival in a transgenic animal model of amyotrophic lateral sclerosis. J Neurochem 2003;85(1):142-50
   PubMed Web of Science ®Google Scholar
• Petri S, Calingasan NY, Alsaied OA, et al. The lipophilic metal chelators DP-109 and DP-460 are neuroprotective in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2007;102(3):991-1000
   PubMed Web of Science ®Google Scholar
• Kupershmidt L, Weinreb O, Amit T, et al. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2009;23(11):3766-79
   PubMed Web of Science ®Google Scholar
• Karlsson J, Fong KS, Hansson MJ, et al. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 2004;101(1):128-37
   Google Scholar
• Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007;322(2):709-20
   PubMed Web of Science ®Google Scholar
• Jiang HQ, Ren M, Jiang HZ, et al. Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis. Neuroscience 2014;277:132-8
   PubMed Web of Science ®Google Scholar
• Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005;93(5):1087-98
   PubMed Web of Science ®Google Scholar
• Del Signore SJ, Amante DJ, Kim J, et al. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotroph Lateral Scler 2009;10(2):85-94
   PubMed Web of Science ®Google Scholar
• Pereira C, Murphy K, Jeschke M, Herndon DN. Post burn muscle wasting and the effects of treatments. Int J Biochem Cell Biol 2005;37(10):1948-61
   PubMed Web of Science ®Google Scholar
• Pedroso FE, Spalding PB, Cheung MC, et al. Inflammation, organomegaly, and muscle wasting despite hyperphagia in a mouse model of burn cachexia. J Cachexia Sarcopenia Muscle 2012;3(3):199-211
   Google Scholar
• Sosic D, Richardson JA, Yu K, et al. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 2003;112(2):169-80
   PubMed Web of Science ®Google Scholar
• Cheng J, Turksen K, Yu QC, et al. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice. Genes Dev 1992;6(8):1444-56
   PubMed Web of Science ®Google Scholar
• Baumgarten A, Bang C, Tschirner A, et al. TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. Int J Cardiol 2013;168(2):1447-52
   PubMed Web of Science ®Google Scholar
• Neo JH, Ager EI, Angus PW, et al. Changes in the renin angiotensin system during the development of colorectal cancer liver metastases. BMC Cancer 2010;10(134):134
   PubMedGoogle Scholar
• Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest 1996;97(11):2509-16
   PubMed Web of Science ®Google Scholar
• Sukhanov S, Semprun-Prieto L, Yoshida T, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci 2011;342(2):143-7
   PubMed Web of Science ®Google Scholar
• Song YH, Li Y, Du J, et al. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005;115(2):451-8
   PubMed Web of Science ®Google Scholar
• Cabassi A, Coghi P, Govoni P, et al. Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat. J Clin Endocrinol Metab 2005;90(5):2888-97
   PubMed Web of Science ®Google Scholar
• Yoshida T, Semprun-Prieto L, Wainford RD, et al. Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus. Endocrinology 2012;153(3):1411-20
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Yamaki A, Furuya M, et al. Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice. Regul Pept 2012;178(1-3):21-8
   PubMed Web of Science ®Google Scholar
• Ma JD, Heavey SF, Revta C, Roeland EJ. Novel investigational biologics for the treatment of cancer cachexia. Expert Opin Biol Ther 2014;14(8):1113-20
   PubMed Web of Science ®Google Scholar
• Strath SJ, Kaminsky LA, Ainsworth BE, et al. Guide to the assessment of physical activity: Clinical and research applications: a scientific statement from the American Heart Association. Circulation 2013;128(20):2259-79
   PubMed Web of Science ®Google Scholar
• Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-15
   PubMed Web of Science ®Google Scholar
• Petruzzelli M, Schweiger M, Schreiber R, et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab 2014;20(3):433-47
   PubMed Web of Science ®Google Scholar
• Kir S, White JP, Kleiner S, et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 2014;513(7516):100-4
   PubMed Web of Science ®Google Scholar
• Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science (New York, NY) 2011;333(6039):233-8
   Google Scholar
• Klein GL, Petschow BW, Shaw AL, Weaver E. Gut barrier dysfunction and microbial translocation in cancer cachexia: a new therapeutic target. Curr Opin Support Palliat Care 2013;7(4):361-7
   PubMed Web of Science ®Google Scholar
• Cramer L, Hildebrandt B, Kung T, et al. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol 2014;64(13):1310-19
   PubMed Web of Science ®Google Scholar
• Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004;91(5):822-8
   PubMed Web of Science ®Google Scholar
• Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2013;61(6):599-610
   PubMed Web of Science ®Google Scholar
• Dyle MC, Ebert SM, Cook DP, et al. Systems-based discovery of tomatidine as a natural small molecule inhibitor of skeletal muscle atrophy. J Biol Chem 2014;289(21):14913-24
   PubMed Web of Science ®Google Scholar
• Kunkel SD, Suneja M, Ebert SM, et al. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab 2011;13(6):627-38
   PubMed Web of Science ®Google Scholar
• Lamb J, Crawford ED, Peck D, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (New York, NY) 2006;313(5795):1929-35
   Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004;3(8):673-83
   PubMed Web of Science ®Google Scholar
• Potsch MS, Tschirner A, Palus S, et al. The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats. J Cachexia Sarcopenia Muscle 2014;5(2):149-58
   Google Scholar
• Palus S, von Haehling S, Flach VC, et al. Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia. Int J Cardiol 2013;168(4):3412-18
   PubMed Web of Science ®Google Scholar